Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of HMR4396 for chemotherapy-associated anaemia
ISRCTN41606826Phase 3Completed
- Sponsor
- Hoechst Marion Roussel (Shire Pharmaceuticals) (France)
- Start
- Aug 2000
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label trial of epoetin delta in anaemia, sponsored by Hoechst Marion Roussel (Shire Pharmaceuticals) (France). Primary endpoint: Change in haemoglobin from baseline. Started Aug 2000; status: completed.
02
Drugs
epoetin delta
03
Conditions
anaemia
Beyond the preview
Go deeper on ISRCTN41606826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN41606826.